Oat-Rich Low-Gluten Diet Modulates Plasma Short-Chain Fatty Acids without Significant Changes in Fecal Microbiome or Inflammatory Markers-A Randomized Clinical Trial in People with Cardiometabolic Risk.
Enni Mannila, Carlos Gómez-Gallego, Geraldson Muluh et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial examined the effects of an oat-rich low-gluten diet (LGD) on plasma short-chain fatty acids (SCFAs), fecal microbiome, and inflammatory markers in 69 individuals with cardiometabolic risk. The study found that the oat-rich LGD significantly increased fasting plasma butyrate levels compared to the rice-rich LGD (P timeXgroup = 0.033), while no significant changes in the fecal microbiome or inflammatory markers were observed.
Key findings
- The oat-rich LGD increased fasting plasma butyrate levels compared to the rice-rich LGD (P timeXgroup = 0.033).
- The rice group exhibited a higher Shannon diversity index post-intervention than the oat group (P TimeXgroup = 0.025).
- No significant changes in inflammatory markers were observed between the groups.
Why it matters
Understanding the impact of dietary composition on plasma SCFAs and microbiome diversity is crucial for managing cardiometabolic risk. This study suggests that incorporating oats into low-gluten diets may enhance beneficial SCFA levels without adversely affecting the microbiome.